Blog Medium

Home Blog Medium

26

Aug2021

Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement

0  
 Shares of Aadi to commence trading on the Nasdaq Capital Market on August 27, 2021 under ticker symbol “AADI”Concurrent $155 ... Read More
August 26, 2021admin

26

Jul2021

Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa

0  
FDA grants Priority Review and sets PDUFA target action date of November 26, 2021LOS ANGELES, July 26, 2021 (GLOBE NEWSWIRE) ... Read More
July 26, 2021admin

07

Jul2021

Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference

0  
LOS ANGELES, July 07, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision ... Read More
July 7, 2021admin

04

Jun2021

Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021

0  
Five of six mTOR inhibitor-naïve patients with TSC1 or TSC2 inactivating alterations achieved confirmed partial responses to single-agent FYARRO Tumor-agnostic ... Read More
June 4, 2021admin